A prospective national observational cohort study

Update generates new list of where clinicians overstep in the pediatric population.

Updated assessment of SCIT and SLIT ahead of upcoming asthma guidelines.

4CMenB has increased immunogenicity compared with rMenB against strain NZ98/254

Prescribers often use regimens of 10 or more days vs recommended 5-7 days.

Introduction at 6-9 months of age may correlate with later benefit.

Risk is higher in older patients than younger ones.

But results are from studies of a dry-powder inhaler unavailable in the US.

Better than placebo, no better than LABAs.

The Innovative Medicines Initiative has launched a new €82 million fund for projects related to immune-mediated diseases.

FDA has fast-tracked peanut powder clinical trials.

Meta-analysis of 51 large-scale studies.

Findings from the UK Fourfold Asthma Study (FAST).

Findings from a meta-analysis.